Eco Animal Regulatory News (EAH)

31 January 2025 

ECO Animal Health Group plc

("ECO" or the "Company")

Board Changes

ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, announces that Dr Andrew Jones, who joined the Board as a Non-executive Director in 2017 and has served as Chairman of the Board since 2019, has stated his intention to retire on 31st March 2025.

As part of a planned succession process, Dr Joachim Hasenmaier joined the Board as a Non-executive Director in February 2024 and will be appointed as Chairman of the Board of ECO on 31st March 2025.

Dr Hasenmaier is a highly experienced commercial leader with more than two decades in the global animal health industry. From 2001 to 2019, he held a variety of senior roles within the animal health division at Boehringer Ingelheim, concluding as member of the Board of Managing Directors responsible for the entire animal health division. During this time, he led successful transformation initiatives including the integration of the former Sanofi animal health business Merial, spearheaded key product launches and supported rapid global growth and expansion.

Dr Andrew Jones stepped down as Chairman of the Nomination Committee on 30 January 2025 and Dr Hasenmaier was appointed as Chairman of the Nomination Committee on the same day. On 31 March 2025, Dr Jones will also step down from the Audit and Remuneration Committees. There will be no further changes to the composition of these committees.

Dr Andrew Jones, outgoing Chairman, commented:

"It has been a privilege to serve as Chairman of ECO Animal Health over the past six years and to work alongside such a talented and dedicated team. After several years as Chairman, I have decided the time is right to retire and I'm delighted to be handing over to someone with such a wealth of experience and expertise. Over the years, we have expanded ECO's global reach, built a robust product portfolio, and laid the groundwork for a strong pipeline of innovative solutions in animal health. Joachim is absolutely the right person to succeed me as Chair, he has a wealth of commercial industry experience and, since joining the Board as a Non-executive Director, has demonstrated solid leadership and expertise."

Dr Joachim Hasenmaier, incoming Chairman, added:

"I am honoured to be appointed Chairman of ECO Animal Health. On behalf of the Board, I would like to thank Andrew for his exceptional leadership, under which ECO has taken great strides in innovation, global reach and product development. ECO is moving into its important next phase with increased focus on the commercialisation of its research and development pipeline. I look forward to working with the Board and the management team to build on this momentum and deliver value for all stakeholders."

-Ends-

For further information please contact:

About ECO Animal Health

ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.

 Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.

 Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry. 

Click here for more information: https://ecoanimalhealth.com